High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain

分享:

简介:

  • 作者: Yaowei Guo, Junliang Chen, Wenyu Ji, Liang Xu, Yu Xie, Shu He, Chuying Lai, Kaiyu Hou, Zeru Li, Gong Chen and Zheng Wu
  • 杂志: Mol Ther Methods Clin Dev
  • Doi: https://www.doi.org/10.1016/j.omtm.2023.08.021
  • 出版日期: 2023 Aug 28

论文中使用的产品/服务

Quotation shows PackGene:AAV vector production and titration SsAAV vectors were used in this study, and all vector genomes were flanked by AAV2/9 (AAV9) or AAV2/5 (AAV5) ITRs. AAV vectors, GFAP-GFP and CAG-Flex-GFP, were constructed by PackGene Biotech. The versions of the GFAP promoter used in this study included GFAP2.2 (2.2-kb gfa2 promoter), GFAP1.6 (1.6-kb GFAP promoter), and GFAP681 (681-bp gfaABC1D promoter). Recombinant AAV9 and AAV5 were produced by PackGene Biotech

Research Field:CNS

AAV Serotype:AAV5, AAV9

Targeted organ:brain

Animal or cell line strain:mouse

询价

摘要

The brain is often described as an “immune-privileged” organ due to the presence of the blood-brain-barrier (BBB), which limits the entry of immune cells. In general, intracranial injection of adeno-associated virus (AAV) is considered a relatively safe procedure. In this study, we discovered that AAV, a popular engineered viral vector for gene therapy, can disrupt the BBB and induce immune cell infiltration in a titer-dependent manner. First, our bulk RNA sequencing data revealed that injection of high-titer AAV significantly upregulated many genes involved in disrupting BBB integrity and antiviral adaptive immune responses. By using histologic analysis, we further demonstrated that the biological structure of the BBB was severely disrupted in the adult mouse brain. Meanwhile, we noticed abnormal leakage of blood components, including immune cells, within the brain parenchyma of high-titer AAV injected areas. Moreover, we identified that the majority of infiltrated immune cells were cytotoxic T lymphocytes (CTLs), which resulted in a massive loss of neurons at the site of AAV injection. In addition, antagonizing CTL function by administering antibodies significantly reduced neuronal toxicity induced by high-titer AAV. Collectively, our findings underscore potential severe side effects of intracranial injection of high-titer AAV, which might compromise proper data interpretation if unaware of.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载